Show
Sort by
-
- Journal Article
- A1
- open access
Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A-rearranged acute myeloid leukemia : a study by the International Berlin-Frankfurt-Münster Study Group
-
- Journal Article
- A1
- open access
Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression : results from the SORAYA study
-
Subcutaneous epcoritamab plus R-DHAX/C in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) eligible for autologous stem cell transplant (ASCT) : preliminary phase 1/2 results
-
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy : CARTITUDE-2, cohort B
-
Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and >= 2 prior therapies : pivotal phase II expansion results
-
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) plus R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL) : phase 1/2 data update
-
- Conference Paper
- C3
- open access
Predicting outcomes with circulating adrenergic neuroblastoma mRNAs in children with relapsed and refractory neuroblastoma : a BEACON-Neuroblastoma biomarker study
-
Short and medium-term outcomes of patients with solid cancer hospitalized with COVID-19 in Belgium according to cancer diagnosis and treatment characteristics
-
- Conference Paper
- C3
- open access
KEYNOTE-B79 phase 1b trial to evaluate the allogeneic CAR T-cells CYAD-101 and pembrolizumab in refractory metastatic colorectal cancer patients
-
- Journal Article
- A1
- open access
Combining Ixazomib with subcutaneous rituximab and dexamethasone in relapsed or refractory Waldenstrom's macroglobulinemia : final analysis of the phase I/II HOVON124/ECWM-R2 study